What is EL219 used for?

EL219 is indicated for Solid tumors (Phase 2 development).

EL219 is developed by Elion Therapeutics, Inc..

What are the side effects of EL219?

Common side effects include Flu-like symptoms, Fatigue, Fever.

Last reviewed 2026-04-23 · How we verify

EL219

Elion Therapeutics, Inc. · Phase 2 active Small molecule

EL219 is an immunostimulatory agent designed to activate innate immune responses against cancer.

EL219 is an immunostimulatory agent designed to activate innate immune responses against cancer. Used for Solid tumors (Phase 2 development).

At a glance

Generic name	EL219
Sponsor	Elion Therapeutics, Inc.
Drug class	TLR7 agonist
Target	TLR7
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

EL219 is a TLR7 agonist that stimulates toll-like receptor 7 signaling to enhance innate immune activation and promote anti-tumor immunity. By triggering pattern recognition receptors on immune cells, it aims to generate robust immune responses against malignant cells. The drug is being developed as a potential therapeutic for various cancers through immune system activation.

Approved indications

Solid tumors (Phase 2 development)

Common side effects

Flu-like symptoms
Fatigue
Fever

Key clinical trials

Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EL219 CI brief — competitive landscape report
EL219 updates RSS · CI watch RSS
Elion Therapeutics, Inc. portfolio CI